Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) — Market Cap & Net Worth
Market Cap & Net Worth: Tonix Pharmaceuticals Holding Corp (TNXP)
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) has a market capitalization of $165.21 Million ($165.21 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17380 globally and #4051 in its home market, demonstrating a -0.68% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tonix Pharmaceuticals Holding Corp's stock price $11.63 by its total outstanding shares 14205401 (14.21 Million). Review total liabilities of Tonix Pharmaceuticals Holding Corp to assess the company's total debt and financial obligations.
Tonix Pharmaceuticals Holding Corp Market Cap History: 2015 to 2026
Tonix Pharmaceuticals Holding Corp's market capitalization history from 2015 to 2026. Data shows change from $14.21 Trillion to $165.21 Million (-65.54% CAGR).
Index Memberships
Tonix Pharmaceuticals Holding Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.01% | #481 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #1709 of 3165 |
Weight: Tonix Pharmaceuticals Holding Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tonix Pharmaceuticals Holding Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tonix Pharmaceuticals Holding Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
16.93x
Tonix Pharmaceuticals Holding Corp's market cap is 16.93 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $61.37 Billion | $2.91 Million | -$50.39 Million | 21059.48x | N/A |
| 2022 | $1.11 Billion | $9.03 Million | -$115.00 Million | 122.68x | N/A |
| 2023 | $183.19 Million | $7.77 Million | -$116.66 Million | 23.58x | N/A |
| 2024 | $4.68 Million | $10.09 Million | -$130.04 Million | 0.46x | N/A |
| 2025 | $221.89 Million | $13.11 Million | -$124.02 Million | 16.93x | N/A |
Competitor Companies of TNXP by Market Capitalization
Companies near Tonix Pharmaceuticals Holding Corp in the global market cap rankings as of June 18, 2026.
Key companies related to Tonix Pharmaceuticals Holding Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Tonix Pharmaceuticals Holding Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, Tonix Pharmaceuticals Holding Corp's market cap moved from $14.21 Trillion to $ 165.21 Million, with a yearly change of -65.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $165.21 Million | -25.54% |
| 2025 | $221.89 Million | +4636.20% |
| 2024 | $4.68 Million | -97.44% |
| 2023 | $183.19 Million | -83.46% |
| 2022 | $1.11 Billion | -96.59% |
| 2021 | $32.52 Billion | -47.01% |
| 2020 | $61.37 Billion | -42.31% |
| 2019 | $106.37 Billion | -94.68% |
| 2018 | $2.00 Trillion | -85.92% |
| 2017 | $14.21 Trillion | 0.00% |
| 2016 | $14.21 Trillion | 0.00% |
| 2015 | $14.21 Trillion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Tonix Pharmaceuticals Holding Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $165.21 Million USD |
| MoneyControl | $165.21 Million USD |
| MarketWatch | $165.21 Million USD |
| marketcap.company | $165.21 Million USD |
| Reuters | $165.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and T… Read more